COMMUNIQUÉS West-GlobeNewswire

Avadel Presents Data on Quality of Life Improvement in Patients on NOCTIVA™ at American Urological Association Western Annual Meeting
29/10/2018
Patients treated with NOCTIVA were three times more likely to report no difficulty getting enough sleep and five times more likely to report no bother due to nocturia DUBLIN, Ireland, Oct. 29, 2018 (GLOBE NEWSWIRE) -- [...]
BioDelivery Sciences Announces Changes to its Executive Leadership Team
29/10/2018
James Vollins joins the Company in role of General Counsel, Chief Compliance Officer, and Corporate Secretary Ernest De Paolantonio, Chief Financial Officer announces plan to retire by mid-2019 Scott Plesha, President [...]
Aura Closes $400,000 Convertible Debenture Offering
29/10/2018
TORONTO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Aura Health Inc. (the " Company " or “ Aura ”) ( CSE: BUZZ ) is very pleased to announce that it has closed a non-brokered private placement offering (the “ Offering ”) on [...]
Aptinyx to Present Preclinical Data on Novel NMDA Receptor Modulators for Pain and Cognition at the 48th Annual Meeting of the Society for Neuroscience
29/10/2018
EVANSTON, Ill., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today [...]
Opiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of Directors
29/10/2018
SANTA MONICA, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, [...]
Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 8
29/10/2018
REHOVOT, Israel, and BRIDGEWATER, N.J., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and [...]
Physeon Receives Institutional Review Board Approval to Commence US "VIVA" Trial for Veinplicity
29/10/2018
Recent Clinical Study Indicated Device had a Dilatory Effect 38% Greater than other Common Approaches for Veins Targeted for IV Access. Other studies indicate a First IV Stick Success Much Greater Than the Standard of [...]
Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER
29/10/2018
STOUGHTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the publication of “Evaluation of the oral human abuse potential of Oxycodone DETERx ® formulation ( [...]
Eidos Therapeutics to Host Conference Call and Webcast to Discuss Phase 2 Clinical Trial Results
29/10/2018
SAN FRANCISCO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Eidos Therapeutics , Inc. (Eidos) (Nasdaq:EIDX) today announced that management will host a conference call and webcast to discuss the results of its Phase 2 clinical [...]
Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP
29/10/2018
– Met primary endpoint of Early Clinical Response at 96 hours after the first dose – – Supplemental NDA expected to be filed with FDA in 1H 2019 – – Baxdela currently FDA approved for treatment of adult patients with [...]
TESARO Announces Achievement of ZEJULA Prostate Cancer Development Milestones by Janssen
29/10/2018
WALTHAM, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO), an oncology-focused biopharmaceutical company, today announced the achievement of development milestones that trigger an $18 million payment [...]
Protech Home Medical Announces Insider Subscriptions
29/10/2018
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CINCINNATI, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Protech Home Medical Corp. (“ PHM ” or the “ Company ”) (TSXV: PHM), is [...]
Iovance Biotherapeutics to Host Melanoma Program Update Event for Analysts and Investors During SITC 2018
29/10/2018
SAN CARLOS, Calif., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology [...]
Loop Industries Endorses the New Plastics Economy Global Commitment – Helping Keep Plastic in the Economy and Out of Nature
29/10/2018
MONTREAL, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Loop Industries, Inc. (Nasdaq: LOOP), a leading technology innovator in sustainable plastic, today announced that it has joined leading global consumer brands, including [...]
HempAmericana Retires All Outstanding Convertible Debt
29/10/2018
NEW YORK, Oct. 29, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- HempAmericana, Inc. (OTC: HMPQ) (“HempAmericana” or the “Company”) is proud to announce the retirement of all outstanding convertible debt. As of the filing [...]
BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update
29/10/2018
Highlights Scientific Advances and Continued Progress for NurOwn ® in ALS Towards U.S. FDA Approval; Following Successful FDA Pre-IND Meeting, BrainStorm will File an IND for NurOwn ® in a Second Clinical Indication [...]
XBiotech annonce de nouveaux brevets au troisième trimestre 2018
29/10/2018
Demande/ autorisation de brevets pour des traitements candidats de la Société destinés aux maladies cardiovasculaires, aux infections par staphylocoque doré et à sa technologie de découverte d’antibiotiques AUSTIN ( [...]
ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals
29/10/2018
ProQR receives exclusive worldwide license for IONIS-RHO-2.5 Rx , now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy A first in human Phase 1/2 [...]
United States Department of Health and Human Services Publishes New HIV Treatment Guidelines Including Trogarzo®
29/10/2018
MONTREAL, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Trogarzo ® (ibalizumab-uiyk) injection is now included in the most recent version of the [...]

Pages